nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—NFATC1—female gonad—testicular cancer	0.0294	0.134	CbGeAlD
Pseudoephedrine—NFATC1—Ectoderm Differentiation—TFAP2C—testicular cancer	0.0293	0.0952	CbGpPWpGaD
Pseudoephedrine—IL2—female gonad—testicular cancer	0.0269	0.123	CbGeAlD
Pseudoephedrine—NFATC1—testis—testicular cancer	0.0261	0.119	CbGeAlD
Pseudoephedrine—NFATC1—BCR signaling pathway—BCL10—testicular cancer	0.0193	0.0628	CbGpPWpGaD
Pseudoephedrine—NFATC1—lymph node—testicular cancer	0.0189	0.0864	CbGeAlD
Pseudoephedrine—TNF—lymph node—testicular cancer	0.0181	0.0824	CbGeAlD
Pseudoephedrine—IL2—lymph node—testicular cancer	0.0173	0.079	CbGeAlD
Pseudoephedrine—NFATC1—TCR Signaling Pathway—BCL10—testicular cancer	0.0153	0.0496	CbGpPWpGaD
Pseudoephedrine—TNF—Canonical NF-kappaB pathway—BCL10—testicular cancer	0.0143	0.0465	CbGpPWpGaD
Pseudoephedrine—Paranoia—Ifosfamide—testicular cancer	0.0118	0.0249	CcSEcCtD
Pseudoephedrine—NFATC1—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—testicular cancer	0.0113	0.0368	CbGpPWpGaD
Pseudoephedrine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.0111	0.0362	CbGpPWpGaD
Pseudoephedrine—Ventricular fibrillation—Ifosfamide—testicular cancer	0.0105	0.0222	CcSEcCtD
Pseudoephedrine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00986	0.032	CbGpPWpGaD
Pseudoephedrine—MAOA—embryo—testicular cancer	0.00959	0.0438	CbGeAlD
Pseudoephedrine—Delirium—Ifosfamide—testicular cancer	0.00935	0.0197	CcSEcCtD
Pseudoephedrine—SLC6A4—NRF2 pathway—SLC2A6—testicular cancer	0.00933	0.0303	CbGpPWpGaD
Pseudoephedrine—MAOA—seminal vesicle—testicular cancer	0.009	0.0411	CbGeAlD
Pseudoephedrine—NFATC1—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.00888	0.0289	CbGpPWpGaD
Pseudoephedrine—SLC6A2—NRF2 pathway—SLC2A6—testicular cancer	0.00802	0.0261	CbGpPWpGaD
Pseudoephedrine—TNF—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00737	0.0239	CbGpPWpGaD
Pseudoephedrine—Pain—Carboplatin—testicular cancer	0.00721	0.0152	CcSEcCtD
Pseudoephedrine—SLC6A3—NRF2 pathway—SLC2A6—testicular cancer	0.00711	0.0231	CbGpPWpGaD
Pseudoephedrine—SLC6A2—gonad—testicular cancer	0.00706	0.0322	CbGeAlD
Pseudoephedrine—ADRA2A—seminal vesicle—testicular cancer	0.00691	0.0315	CbGeAlD
Pseudoephedrine—Angina pectoris—Vinblastine—testicular cancer	0.00681	0.0144	CcSEcCtD
Pseudoephedrine—Body temperature increased—Carboplatin—testicular cancer	0.00666	0.0141	CcSEcCtD
Pseudoephedrine—ADRB1—G alpha (s) signalling events—INSL3—testicular cancer	0.00642	0.0209	CbGpPWpGaD
Pseudoephedrine—SLC6A3—testis—testicular cancer	0.00631	0.0288	CbGeAlD
Pseudoephedrine—ADRB2—G alpha (s) signalling events—INSL3—testicular cancer	0.00628	0.0204	CbGpPWpGaD
Pseudoephedrine—Hallucination—Chlorambucil—testicular cancer	0.00607	0.0128	CcSEcCtD
Pseudoephedrine—Psychotic disorder—Ifosfamide—testicular cancer	0.0057	0.012	CcSEcCtD
Pseudoephedrine—Urinary retention—Ifosfamide—testicular cancer	0.00555	0.0117	CcSEcCtD
Pseudoephedrine—NFATC1—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.00536	0.0174	CbGpPWpGaD
Pseudoephedrine—MAOA—female gonad—testicular cancer	0.00529	0.0241	CbGeAlD
Pseudoephedrine—SLC6A2—testis—testicular cancer	0.00509	0.0232	CbGeAlD
Pseudoephedrine—SLC6A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00506	0.0164	CbGpPWpGaD
Pseudoephedrine—ADRA2A—gonad—testicular cancer	0.00499	0.0228	CbGeAlD
Pseudoephedrine—Tremor—Chlorambucil—testicular cancer	0.00498	0.0105	CcSEcCtD
Pseudoephedrine—Angina pectoris—Ifosfamide—testicular cancer	0.00491	0.0104	CcSEcCtD
Pseudoephedrine—Agitation—Chlorambucil—testicular cancer	0.00488	0.0103	CcSEcCtD
Pseudoephedrine—Irritability—Cisplatin—testicular cancer	0.0048	0.0101	CcSEcCtD
Pseudoephedrine—NFATC1—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.00477	0.0155	CbGpPWpGaD
Pseudoephedrine—Dysuria—Ifosfamide—testicular cancer	0.00472	0.00997	CcSEcCtD
Pseudoephedrine—MAOA—testis—testicular cancer	0.00469	0.0214	CbGeAlD
Pseudoephedrine—SLC6A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00448	0.0146	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.00443	0.0144	CbGpPWpGaD
Pseudoephedrine—Vertigo—Vinblastine—testicular cancer	0.00437	0.00924	CcSEcCtD
Pseudoephedrine—Confusional state—Chlorambucil—testicular cancer	0.00437	0.00924	CcSEcCtD
Pseudoephedrine—TNF—Matrix Metalloproteinases—MMP2—testicular cancer	0.00422	0.0137	CbGpPWpGaD
Pseudoephedrine—Hypertension—Vinblastine—testicular cancer	0.0042	0.00888	CcSEcCtD
Pseudoephedrine—IL2—GPCR downstream signaling—INSL3—testicular cancer	0.0042	0.0136	CbGpPWpGaD
Pseudoephedrine—Delirium—Epirubicin—testicular cancer	0.00414	0.00874	CcSEcCtD
Pseudoephedrine—Anorexia—Chlorambucil—testicular cancer	0.00413	0.00873	CcSEcCtD
Pseudoephedrine—Bradycardia—Ifosfamide—testicular cancer	0.00411	0.00868	CcSEcCtD
Pseudoephedrine—ADRA2A—female gonad—testicular cancer	0.00406	0.0185	CbGeAlD
Pseudoephedrine—Hallucination—Ifosfamide—testicular cancer	0.00402	0.00849	CcSEcCtD
Pseudoephedrine—TNF—amb2 Integrin signaling—MMP2—testicular cancer	0.004	0.013	CbGpPWpGaD
Pseudoephedrine—NFATC1—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.00398	0.0129	CbGpPWpGaD
Pseudoephedrine—Delirium—Doxorubicin—testicular cancer	0.00383	0.00809	CcSEcCtD
Pseudoephedrine—Dyspepsia—Chlorambucil—testicular cancer	0.00382	0.00807	CcSEcCtD
Pseudoephedrine—IL2—Signaling by GPCR—INSL3—testicular cancer	0.00381	0.0124	CbGpPWpGaD
Pseudoephedrine—Anorexia—Vinblastine—testicular cancer	0.00379	0.008	CcSEcCtD
Pseudoephedrine—Decreased appetite—Chlorambucil—testicular cancer	0.00377	0.00796	CcSEcCtD
Pseudoephedrine—TNF—Developmental Biology—PRDM14—testicular cancer	0.00373	0.0121	CbGpPWpGaD
Pseudoephedrine—Pain—Chlorambucil—testicular cancer	0.00371	0.00784	CcSEcCtD
Pseudoephedrine—SLC6A2—lymph node—testicular cancer	0.00369	0.0168	CbGeAlD
Pseudoephedrine—NFATC1—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.00365	0.0119	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling by Wnt—H2AFZ—testicular cancer	0.00365	0.0119	CbGpPWpGaD
Pseudoephedrine—Arrhythmia—Ifosfamide—testicular cancer	0.00361	0.00762	CcSEcCtD
Pseudoephedrine—ADRA2A—testis—testicular cancer	0.0036	0.0164	CbGeAlD
Pseudoephedrine—Feeling abnormal—Chlorambucil—testicular cancer	0.00357	0.00755	CcSEcCtD
Pseudoephedrine—Bradycardia—Cisplatin—testicular cancer	0.00354	0.00749	CcSEcCtD
Pseudoephedrine—Chest pain—Bleomycin—testicular cancer	0.0035	0.0074	CcSEcCtD
Pseudoephedrine—Decreased appetite—Vinblastine—testicular cancer	0.00345	0.0073	CcSEcCtD
Pseudoephedrine—NFATC1—Innate Immune System—BCL10—testicular cancer	0.00345	0.0112	CbGpPWpGaD
Pseudoephedrine—Body temperature increased—Chlorambucil—testicular cancer	0.00343	0.00724	CcSEcCtD
Pseudoephedrine—MAOA—lymph node—testicular cancer	0.0034	0.0155	CbGeAlD
Pseudoephedrine—Pain—Vinblastine—testicular cancer	0.0034	0.00718	CcSEcCtD
Pseudoephedrine—Confusional state—Bleomycin—testicular cancer	0.00338	0.00715	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Vinblastine—testicular cancer	0.00327	0.00692	CcSEcCtD
Pseudoephedrine—Agitation—Ifosfamide—testicular cancer	0.00323	0.00682	CcSEcCtD
Pseudoephedrine—Anorexia—Bleomycin—testicular cancer	0.0032	0.00676	CcSEcCtD
Pseudoephedrine—Vertigo—Ifosfamide—testicular cancer	0.00316	0.00667	CcSEcCtD
Pseudoephedrine—CYP2D6—female gonad—testicular cancer	0.00314	0.0143	CbGeAlD
Pseudoephedrine—Asthenia—Chlorambucil—testicular cancer	0.00311	0.00657	CcSEcCtD
Pseudoephedrine—Arrhythmia—Cisplatin—testicular cancer	0.00311	0.00657	CcSEcCtD
Pseudoephedrine—Palpitations—Ifosfamide—testicular cancer	0.00311	0.00656	CcSEcCtD
Pseudoephedrine—ADRB1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00306	0.00994	CbGpPWpGaD
Pseudoephedrine—Hypertension—Ifosfamide—testicular cancer	0.00303	0.00641	CcSEcCtD
Pseudoephedrine—Dyspnoea—Bleomycin—testicular cancer	0.00299	0.00632	CcSEcCtD
Pseudoephedrine—ADRB2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00299	0.00972	CbGpPWpGaD
Pseudoephedrine—Chest pain—Ifosfamide—testicular cancer	0.00299	0.00632	CcSEcCtD
Pseudoephedrine—Anorexia—Dactinomycin—testicular cancer	0.00298	0.0063	CcSEcCtD
Pseudoephedrine—Decreased appetite—Bleomycin—testicular cancer	0.00292	0.00616	CcSEcCtD
Pseudoephedrine—Muscle spasms—Cisplatin—testicular cancer	0.00291	0.00615	CcSEcCtD
Pseudoephedrine—Confusional state—Ifosfamide—testicular cancer	0.00289	0.00611	CcSEcCtD
Pseudoephedrine—Pain—Bleomycin—testicular cancer	0.00287	0.00606	CcSEcCtD
Pseudoephedrine—Asthenia—Vinblastine—testicular cancer	0.00285	0.00602	CcSEcCtD
Pseudoephedrine—Tremor—Cisplatin—testicular cancer	0.00284	0.006	CcSEcCtD
Pseudoephedrine—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—testicular cancer	0.0028	0.0091	CbGpPWpGaD
Pseudoephedrine—CYP2D6—testis—testicular cancer	0.00279	0.0127	CbGeAlD
Pseudoephedrine—Hyperhidrosis—Ifosfamide—testicular cancer	0.00277	0.00586	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Bleomycin—testicular cancer	0.00277	0.00584	CcSEcCtD
Pseudoephedrine—Vomiting—Chlorambucil—testicular cancer	0.00276	0.00583	CcSEcCtD
Pseudoephedrine—Anorexia—Ifosfamide—testicular cancer	0.00273	0.00578	CcSEcCtD
Pseudoephedrine—Decreased appetite—Dactinomycin—testicular cancer	0.00272	0.00575	CcSEcCtD
Pseudoephedrine—Pain—Dactinomycin—testicular cancer	0.00268	0.00566	CcSEcCtD
Pseudoephedrine—Muscle spasms—Etoposide—testicular cancer	0.00267	0.00564	CcSEcCtD
Pseudoephedrine—NFATC1—Signaling Pathways—INSL3—testicular cancer	0.00266	0.00865	CbGpPWpGaD
Pseudoephedrine—Body temperature increased—Bleomycin—testicular cancer	0.00265	0.00561	CcSEcCtD
Pseudoephedrine—ADRA1A—AMPK Signaling—STK11—testicular cancer	0.00264	0.00858	CbGpPWpGaD
Pseudoephedrine—Irritability—Methotrexate—testicular cancer	0.00264	0.00557	CcSEcCtD
Pseudoephedrine—Dizziness—Vinblastine—testicular cancer	0.00263	0.00555	CcSEcCtD
Pseudoephedrine—ADRA2A—lymph node—testicular cancer	0.00261	0.0119	CbGeAlD
Pseudoephedrine—Feeling abnormal—Dactinomycin—testicular cancer	0.00258	0.00545	CcSEcCtD
Pseudoephedrine—Nausea—Chlorambucil—testicular cancer	0.00258	0.00544	CcSEcCtD
Pseudoephedrine—Anxiety—Cisplatin—testicular cancer	0.00257	0.00543	CcSEcCtD
Pseudoephedrine—SLC6A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00257	0.00835	CbGpPWpGaD
Pseudoephedrine—Dyspnoea—Ifosfamide—testicular cancer	0.00256	0.0054	CcSEcCtD
Pseudoephedrine—Vomiting—Vinblastine—testicular cancer	0.00253	0.00534	CcSEcCtD
Pseudoephedrine—Vertigo—Etoposide—testicular cancer	0.00249	0.00527	CcSEcCtD
Pseudoephedrine—Decreased appetite—Ifosfamide—testicular cancer	0.00249	0.00527	CcSEcCtD
Pseudoephedrine—Headache—Vinblastine—testicular cancer	0.00249	0.00526	CcSEcCtD
Pseudoephedrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00247	0.00804	CbGpPWpGaD
Pseudoephedrine—Body temperature increased—Dactinomycin—testicular cancer	0.00247	0.00523	CcSEcCtD
Pseudoephedrine—Pain—Ifosfamide—testicular cancer	0.00245	0.00518	CcSEcCtD
Pseudoephedrine—MAOA—Biological oxidations—HPGDS—testicular cancer	0.00243	0.00791	CbGpPWpGaD
Pseudoephedrine—Tachycardia—Cisplatin—testicular cancer	0.00241	0.0051	CcSEcCtD
Pseudoephedrine—Asthenia—Bleomycin—testicular cancer	0.00241	0.00509	CcSEcCtD
Pseudoephedrine—Hypertension—Etoposide—testicular cancer	0.0024	0.00506	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Cisplatin—testicular cancer	0.00239	0.00505	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Ifosfamide—testicular cancer	0.00236	0.00499	CcSEcCtD
Pseudoephedrine—Chest pain—Etoposide—testicular cancer	0.00236	0.00499	CcSEcCtD
Pseudoephedrine—Nausea—Vinblastine—testicular cancer	0.00236	0.00499	CcSEcCtD
Pseudoephedrine—TNF—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00236	0.00767	CbGpPWpGaD
Pseudoephedrine—Anorexia—Cisplatin—testicular cancer	0.00236	0.00498	CcSEcCtD
Pseudoephedrine—ADRB1—GPCR ligand binding—INSL3—testicular cancer	0.00233	0.00757	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.0023	0.00747	CbGpPWpGaD
Pseudoephedrine—Confusional state—Etoposide—testicular cancer	0.00228	0.00483	CcSEcCtD
Pseudoephedrine—ADRB2—GPCR ligand binding—INSL3—testicular cancer	0.00228	0.0074	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00228	0.0074	CbGpPWpGaD
Pseudoephedrine—Body temperature increased—Ifosfamide—testicular cancer	0.00227	0.00479	CcSEcCtD
Pseudoephedrine—IL2—Signaling Pathways—INSL3—testicular cancer	0.00225	0.00731	CbGpPWpGaD
Pseudoephedrine—Asthenia—Dactinomycin—testicular cancer	0.00225	0.00475	CcSEcCtD
Pseudoephedrine—Dysuria—Methotrexate—testicular cancer	0.00223	0.00471	CcSEcCtD
Pseudoephedrine—Tachycardia—Etoposide—testicular cancer	0.00221	0.00467	CcSEcCtD
Pseudoephedrine—Dyspnoea—Cisplatin—testicular cancer	0.0022	0.00466	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Etoposide—testicular cancer	0.00219	0.00463	CcSEcCtD
Pseudoephedrine—Angina pectoris—Epirubicin—testicular cancer	0.00218	0.0046	CcSEcCtD
Pseudoephedrine—Anorexia—Etoposide—testicular cancer	0.00216	0.00456	CcSEcCtD
Pseudoephedrine—Decreased appetite—Cisplatin—testicular cancer	0.00215	0.00454	CcSEcCtD
Pseudoephedrine—Vomiting—Bleomycin—testicular cancer	0.00213	0.00451	CcSEcCtD
Pseudoephedrine—Rash—Bleomycin—testicular cancer	0.00212	0.00447	CcSEcCtD
Pseudoephedrine—Pain—Cisplatin—testicular cancer	0.00211	0.00447	CcSEcCtD
Pseudoephedrine—Dermatitis—Bleomycin—testicular cancer	0.00211	0.00447	CcSEcCtD
Pseudoephedrine—Dysuria—Epirubicin—testicular cancer	0.00209	0.00441	CcSEcCtD
Pseudoephedrine—NFATC1—Innate Immune System—KITLG—testicular cancer	0.00208	0.00676	CbGpPWpGaD
Pseudoephedrine—Asthenia—Ifosfamide—testicular cancer	0.00206	0.00435	CcSEcCtD
Pseudoephedrine—Sweating—Methotrexate—testicular cancer	0.00204	0.00431	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Cisplatin—testicular cancer	0.00204	0.00431	CcSEcCtD
Pseudoephedrine—Dyspnoea—Etoposide—testicular cancer	0.00202	0.00427	CcSEcCtD
Pseudoephedrine—Angina pectoris—Doxorubicin—testicular cancer	0.00201	0.00425	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—BCL10—testicular cancer	0.00201	0.00653	CbGpPWpGaD
Pseudoephedrine—Nausea—Bleomycin—testicular cancer	0.00199	0.00421	CcSEcCtD
Pseudoephedrine—Vomiting—Dactinomycin—testicular cancer	0.00199	0.0042	CcSEcCtD
Pseudoephedrine—Rash—Dactinomycin—testicular cancer	0.00197	0.00417	CcSEcCtD
Pseudoephedrine—Decreased appetite—Etoposide—testicular cancer	0.00197	0.00416	CcSEcCtD
Pseudoephedrine—Body temperature increased—Cisplatin—testicular cancer	0.00195	0.00413	CcSEcCtD
Pseudoephedrine—Pain—Etoposide—testicular cancer	0.00194	0.00409	CcSEcCtD
Pseudoephedrine—Dysuria—Doxorubicin—testicular cancer	0.00193	0.00408	CcSEcCtD
Pseudoephedrine—Sweating—Epirubicin—testicular cancer	0.00191	0.00403	CcSEcCtD
Pseudoephedrine—Dizziness—Ifosfamide—testicular cancer	0.0019	0.00401	CcSEcCtD
Pseudoephedrine—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	0.00188	0.00612	CbGpPWpGaD
Pseudoephedrine—Feeling abnormal—Etoposide—testicular cancer	0.00187	0.00394	CcSEcCtD
Pseudoephedrine—Nausea—Dactinomycin—testicular cancer	0.00186	0.00393	CcSEcCtD
Pseudoephedrine—Vomiting—Ifosfamide—testicular cancer	0.00182	0.00385	CcSEcCtD
Pseudoephedrine—Bradycardia—Epirubicin—testicular cancer	0.00182	0.00384	CcSEcCtD
Pseudoephedrine—Rash—Ifosfamide—testicular cancer	0.00181	0.00382	CcSEcCtD
Pseudoephedrine—Dermatitis—Ifosfamide—testicular cancer	0.00181	0.00382	CcSEcCtD
Pseudoephedrine—Body temperature increased—Etoposide—testicular cancer	0.00179	0.00378	CcSEcCtD
Pseudoephedrine—Asthenia—Cisplatin—testicular cancer	0.00177	0.00375	CcSEcCtD
Pseudoephedrine—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	0.00177	0.00574	CbGpPWpGaD
Pseudoephedrine—Sweating—Doxorubicin—testicular cancer	0.00177	0.00373	CcSEcCtD
Pseudoephedrine—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	0.00175	0.00569	CbGpPWpGaD
Pseudoephedrine—TNF—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00171	0.00557	CbGpPWpGaD
Pseudoephedrine—Nausea—Ifosfamide—testicular cancer	0.0017	0.0036	CcSEcCtD
Pseudoephedrine—IL2—Immune System—BCL10—testicular cancer	0.0017	0.00552	CbGpPWpGaD
Pseudoephedrine—Bradycardia—Doxorubicin—testicular cancer	0.00168	0.00356	CcSEcCtD
Pseudoephedrine—Asthenia—Etoposide—testicular cancer	0.00163	0.00343	CcSEcCtD
Pseudoephedrine—Arrhythmia—Epirubicin—testicular cancer	0.0016	0.00337	CcSEcCtD
Pseudoephedrine—Vomiting—Cisplatin—testicular cancer	0.00157	0.00332	CcSEcCtD
Pseudoephedrine—Rash—Cisplatin—testicular cancer	0.00156	0.00329	CcSEcCtD
Pseudoephedrine—Dermatitis—Cisplatin—testicular cancer	0.00156	0.00329	CcSEcCtD
Pseudoephedrine—NFATC1—Innate Immune System—FGFR3—testicular cancer	0.00155	0.00503	CbGpPWpGaD
Pseudoephedrine—Tension—Epirubicin—testicular cancer	0.00153	0.00323	CcSEcCtD
Pseudoephedrine—Nervousness—Epirubicin—testicular cancer	0.00151	0.00319	CcSEcCtD
Pseudoephedrine—Dizziness—Etoposide—testicular cancer	0.0015	0.00317	CcSEcCtD
Pseudoephedrine—Muscle spasms—Epirubicin—testicular cancer	0.0015	0.00316	CcSEcCtD
Pseudoephedrine—Vertigo—Methotrexate—testicular cancer	0.00149	0.00316	CcSEcCtD
Pseudoephedrine—Arrhythmia—Doxorubicin—testicular cancer	0.00148	0.00312	CcSEcCtD
Pseudoephedrine—Nausea—Cisplatin—testicular cancer	0.00147	0.0031	CcSEcCtD
Pseudoephedrine—Vomiting—Etoposide—testicular cancer	0.00144	0.00304	CcSEcCtD
Pseudoephedrine—Agitation—Epirubicin—testicular cancer	0.00143	0.00302	CcSEcCtD
Pseudoephedrine—Rash—Etoposide—testicular cancer	0.00143	0.00302	CcSEcCtD
Pseudoephedrine—Dermatitis—Etoposide—testicular cancer	0.00143	0.00302	CcSEcCtD
Pseudoephedrine—NFATC1—Innate Immune System—KIT—testicular cancer	0.00142	0.00461	CbGpPWpGaD
Pseudoephedrine—Headache—Etoposide—testicular cancer	0.00142	0.003	CcSEcCtD
Pseudoephedrine—Chest pain—Methotrexate—testicular cancer	0.00142	0.00299	CcSEcCtD
Pseudoephedrine—Tension—Doxorubicin—testicular cancer	0.00141	0.00299	CcSEcCtD
Pseudoephedrine—Nervousness—Doxorubicin—testicular cancer	0.0014	0.00295	CcSEcCtD
Pseudoephedrine—Vertigo—Epirubicin—testicular cancer	0.0014	0.00295	CcSEcCtD
Pseudoephedrine—Muscle spasms—Doxorubicin—testicular cancer	0.00138	0.00292	CcSEcCtD
Pseudoephedrine—Palpitations—Epirubicin—testicular cancer	0.00138	0.00291	CcSEcCtD
Pseudoephedrine—Confusional state—Methotrexate—testicular cancer	0.00137	0.00289	CcSEcCtD
Pseudoephedrine—Nausea—Etoposide—testicular cancer	0.00135	0.00284	CcSEcCtD
Pseudoephedrine—Hypertension—Epirubicin—testicular cancer	0.00134	0.00284	CcSEcCtD
Pseudoephedrine—Chest pain—Epirubicin—testicular cancer	0.00132	0.0028	CcSEcCtD
Pseudoephedrine—Agitation—Doxorubicin—testicular cancer	0.00132	0.0028	CcSEcCtD
Pseudoephedrine—Anxiety—Epirubicin—testicular cancer	0.00132	0.00279	CcSEcCtD
Pseudoephedrine—ADRB1—GPCR downstream signaling—INSL3—testicular cancer	0.00132	0.00428	CbGpPWpGaD
Pseudoephedrine—Hyperhidrosis—Methotrexate—testicular cancer	0.00131	0.00277	CcSEcCtD
Pseudoephedrine—Vertigo—Doxorubicin—testicular cancer	0.00129	0.00273	CcSEcCtD
Pseudoephedrine—Anorexia—Methotrexate—testicular cancer	0.00129	0.00273	CcSEcCtD
Pseudoephedrine—ADRB2—GPCR downstream signaling—INSL3—testicular cancer	0.00129	0.00418	CbGpPWpGaD
Pseudoephedrine—Confusional state—Epirubicin—testicular cancer	0.00128	0.00271	CcSEcCtD
Pseudoephedrine—Palpitations—Doxorubicin—testicular cancer	0.00127	0.00269	CcSEcCtD
Pseudoephedrine—Hypertension—Doxorubicin—testicular cancer	0.00124	0.00263	CcSEcCtD
Pseudoephedrine—Tachycardia—Epirubicin—testicular cancer	0.00124	0.00262	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Epirubicin—testicular cancer	0.00123	0.00259	CcSEcCtD
Pseudoephedrine—Insomnia—Methotrexate—testicular cancer	0.00123	0.00259	CcSEcCtD
Pseudoephedrine—Chest pain—Doxorubicin—testicular cancer	0.00123	0.00259	CcSEcCtD
Pseudoephedrine—Anxiety—Doxorubicin—testicular cancer	0.00122	0.00258	CcSEcCtD
Pseudoephedrine—NFATC1—Disease—H2AFZ—testicular cancer	0.00122	0.00395	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—KITLG—testicular cancer	0.00121	0.00394	CbGpPWpGaD
Pseudoephedrine—Anorexia—Epirubicin—testicular cancer	0.00121	0.00256	CcSEcCtD
Pseudoephedrine—Dyspnoea—Methotrexate—testicular cancer	0.00121	0.00256	CcSEcCtD
Pseudoephedrine—ADRB1—Signaling by GPCR—INSL3—testicular cancer	0.0012	0.00388	CbGpPWpGaD
Pseudoephedrine—Dyspepsia—Methotrexate—testicular cancer	0.00119	0.00252	CcSEcCtD
Pseudoephedrine—Confusional state—Doxorubicin—testicular cancer	0.00118	0.0025	CcSEcCtD
Pseudoephedrine—Decreased appetite—Methotrexate—testicular cancer	0.00118	0.00249	CcSEcCtD
Pseudoephedrine—ADRB2—Signaling by GPCR—INSL3—testicular cancer	0.00117	0.0038	CbGpPWpGaD
Pseudoephedrine—Pain—Methotrexate—testicular cancer	0.00116	0.00245	CcSEcCtD
Pseudoephedrine—Insomnia—Epirubicin—testicular cancer	0.00115	0.00243	CcSEcCtD
Pseudoephedrine—Tachycardia—Doxorubicin—testicular cancer	0.00115	0.00242	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Doxorubicin—testicular cancer	0.00114	0.0024	CcSEcCtD
Pseudoephedrine—Dyspnoea—Epirubicin—testicular cancer	0.00113	0.00239	CcSEcCtD
Pseudoephedrine—Anorexia—Doxorubicin—testicular cancer	0.00112	0.00237	CcSEcCtD
Pseudoephedrine—NFATC1—Disease—KITLG—testicular cancer	0.00112	0.00364	CbGpPWpGaD
Pseudoephedrine—Feeling abnormal—Methotrexate—testicular cancer	0.00112	0.00236	CcSEcCtD
Pseudoephedrine—Dyspepsia—Epirubicin—testicular cancer	0.00112	0.00236	CcSEcCtD
Pseudoephedrine—Decreased appetite—Epirubicin—testicular cancer	0.0011	0.00233	CcSEcCtD
Pseudoephedrine—Pain—Epirubicin—testicular cancer	0.00109	0.00229	CcSEcCtD
Pseudoephedrine—Body temperature increased—Methotrexate—testicular cancer	0.00107	0.00227	CcSEcCtD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	0.00107	0.00346	CbGpPWpGaD
Pseudoephedrine—Insomnia—Doxorubicin—testicular cancer	0.00106	0.00225	CcSEcCtD
Pseudoephedrine—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.00106	0.00344	CbGpPWpGaD
Pseudoephedrine—Dyspnoea—Doxorubicin—testicular cancer	0.00105	0.00221	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Epirubicin—testicular cancer	0.00105	0.00221	CcSEcCtD
Pseudoephedrine—Dyspepsia—Doxorubicin—testicular cancer	0.00103	0.00219	CcSEcCtD
Pseudoephedrine—IL2—Immune System—KITLG—testicular cancer	0.00102	0.00333	CbGpPWpGaD
Pseudoephedrine—Decreased appetite—Doxorubicin—testicular cancer	0.00102	0.00216	CcSEcCtD
Pseudoephedrine—Pain—Doxorubicin—testicular cancer	0.001	0.00212	CcSEcCtD
Pseudoephedrine—Body temperature increased—Epirubicin—testicular cancer	0.001	0.00212	CcSEcCtD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	0.00099	0.00322	CbGpPWpGaD
Pseudoephedrine—Asthenia—Methotrexate—testicular cancer	0.000974	0.00206	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Doxorubicin—testicular cancer	0.000968	0.00205	CcSEcCtD
Pseudoephedrine—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	0.000967	0.00314	CbGpPWpGaD
Pseudoephedrine—Body temperature increased—Doxorubicin—testicular cancer	0.000929	0.00196	CcSEcCtD
Pseudoephedrine—Asthenia—Epirubicin—testicular cancer	0.000911	0.00193	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—FGFR3—testicular cancer	0.000901	0.00293	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	0.000899	0.00292	CbGpPWpGaD
Pseudoephedrine—Dizziness—Methotrexate—testicular cancer	0.000897	0.0019	CcSEcCtD
Pseudoephedrine—Vomiting—Methotrexate—testicular cancer	0.000863	0.00182	CcSEcCtD
Pseudoephedrine—Rash—Methotrexate—testicular cancer	0.000856	0.00181	CcSEcCtD
Pseudoephedrine—Dermatitis—Methotrexate—testicular cancer	0.000855	0.00181	CcSEcCtD
Pseudoephedrine—NFATC1—Signaling Pathways—H2AFZ—testicular cancer	0.000852	0.00277	CbGpPWpGaD
Pseudoephedrine—Headache—Methotrexate—testicular cancer	0.00085	0.0018	CcSEcCtD
Pseudoephedrine—NFATC1—Signaling Pathways—STK11—testicular cancer	0.000847	0.00275	CbGpPWpGaD
Pseudoephedrine—Asthenia—Doxorubicin—testicular cancer	0.000843	0.00178	CcSEcCtD
Pseudoephedrine—Dizziness—Epirubicin—testicular cancer	0.00084	0.00177	CcSEcCtD
Pseudoephedrine—NFATC1—Disease—FGFR3—testicular cancer	0.000832	0.0027	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—KIT—testicular cancer	0.000827	0.00269	CbGpPWpGaD
Pseudoephedrine—Vomiting—Epirubicin—testicular cancer	0.000807	0.00171	CcSEcCtD
Pseudoephedrine—Nausea—Methotrexate—testicular cancer	0.000806	0.0017	CcSEcCtD
Pseudoephedrine—Rash—Epirubicin—testicular cancer	0.000801	0.00169	CcSEcCtD
Pseudoephedrine—Dermatitis—Epirubicin—testicular cancer	0.0008	0.00169	CcSEcCtD
Pseudoephedrine—Headache—Epirubicin—testicular cancer	0.000796	0.00168	CcSEcCtD
Pseudoephedrine—NFATC1—Signaling Pathways—KITLG—testicular cancer	0.000784	0.00255	CbGpPWpGaD
Pseudoephedrine—Dizziness—Doxorubicin—testicular cancer	0.000777	0.00164	CcSEcCtD
Pseudoephedrine—NFATC1—Disease—KIT—testicular cancer	0.000763	0.00248	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—FGFR3—testicular cancer	0.000762	0.00248	CbGpPWpGaD
Pseudoephedrine—Nausea—Epirubicin—testicular cancer	0.000754	0.00159	CcSEcCtD
Pseudoephedrine—Vomiting—Doxorubicin—testicular cancer	0.000747	0.00158	CcSEcCtD
Pseudoephedrine—Rash—Doxorubicin—testicular cancer	0.000741	0.00157	CcSEcCtD
Pseudoephedrine—Dermatitis—Doxorubicin—testicular cancer	0.00074	0.00156	CcSEcCtD
Pseudoephedrine—Headache—Doxorubicin—testicular cancer	0.000736	0.00156	CcSEcCtD
Pseudoephedrine—IL2—Signaling Pathways—H2AFZ—testicular cancer	0.00072	0.00234	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—STK11—testicular cancer	0.000716	0.00233	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—INSL3—testicular cancer	0.000706	0.00229	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—KIT—testicular cancer	0.000699	0.00227	CbGpPWpGaD
Pseudoephedrine—Nausea—Doxorubicin—testicular cancer	0.000698	0.00147	CcSEcCtD
Pseudoephedrine—ADRB2—Signaling Pathways—INSL3—testicular cancer	0.000691	0.00224	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—KITLG—testicular cancer	0.000663	0.00215	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—FGFR3—testicular cancer	0.000582	0.00189	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—INSL3—testicular cancer	0.000571	0.00186	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—KIT—testicular cancer	0.000535	0.00174	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—INSL3—testicular cancer	0.000531	0.00173	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—FGFR3—testicular cancer	0.000493	0.0016	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—KIT—testicular cancer	0.000452	0.00147	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—MMP2—testicular cancer	0.000448	0.00146	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—HPGDS—testicular cancer	0.000416	0.00135	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—STK11—testicular cancer	0.000302	0.000983	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—HPGDS—testicular cancer	0.000278	0.000904	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—H2AFZ—testicular cancer	0.000226	0.000735	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—STK11—testicular cancer	0.000225	0.00073	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—H2AFZ—testicular cancer	0.000221	0.000719	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—STK11—testicular cancer	0.00022	0.000714	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KITLG—testicular cancer	0.000208	0.000676	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KITLG—testicular cancer	0.000203	0.000661	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—STK11—testicular cancer	0.000202	0.000657	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	0.000183	0.000594	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—STK11—testicular cancer	0.000182	0.000591	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—HPGDS—testicular cancer	0.000181	0.000589	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	0.00017	0.000552	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—STK11—testicular cancer	0.000169	0.000549	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KITLG—testicular cancer	0.000168	0.000547	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KITLG—testicular cancer	0.000156	0.000508	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—FGFR3—testicular cancer	0.000155	0.000502	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—FGFR3—testicular cancer	0.000151	0.000491	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KIT—testicular cancer	0.000142	0.000461	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KIT—testicular cancer	0.000139	0.000451	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—STK11—testicular cancer	0.000132	0.000428	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	0.000125	0.000406	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	0.000116	0.000378	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KIT—testicular cancer	0.000115	0.000373	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KIT—testicular cancer	0.000107	0.000347	CbGpPWpGaD
